Company intelligence / Profile preview
Shanghai Meiyue Biotech Development
Shanghai, Chinameiyue.com ↗
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
Shanghai Meiyue Biotech Development is actively researching small molecule inhibitors targeting complement pathways (notably complement factor B) and kinases (MAPK p38, IRAK4). Its leading assets are at the pre-clinical stage with a focus on autoimmune, hematological, and ocular diseases, with public disclosures of new chemical entities but no reported clinical efficacy or human data yet.[6][7][10]
- Therapeutic areas
- ImmunologyNephrologyRheumatologyOphthalmologyHematologyDermatologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Shandong Galaxy Bio-Tech
Beyond the preview
Go deeper on Shanghai Meiyue Biotech Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Meiyue Biotech Development.